Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2010 3
2012 2
2013 5
2014 3
2015 3
2016 1
2017 1
2019 1
2020 2
2023 1
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry.
Harada H, Kondo M, Maeyama A, Fukuda T, Ikemura S, Shono E, Tsuru T, Inoue Y, Yoshizawa S, Niiro H, Nakashima Y. Harada H, et al. Among authors: shono e. Clin Rheumatol. 2024 May;43(5):1447-1459. doi: 10.1007/s10067-023-06862-8. Epub 2024 Jan 6. Clin Rheumatol. 2024. PMID: 38182801
Abatacept reduces disease activity of rheumatoid arthritis independently of modulating anti-citrullinated peptide antibody production.
Yamada H, Tsuru T, Otsuka T, Maekawa M, Harada H, Fukuda T, Tsukamoto H, Maeyama A, Yoshizawa S, Wada K, Nakashima Y, Shono E, Yoshizawa S, Jojima H, Kondo M. Yamada H, et al. Among authors: shono e. Immunol Med. 2020 Jun;43(2):87-91. doi: 10.1080/25785826.2020.1718833. Epub 2020 Jan 29. Immunol Med. 2020. PMID: 31994996 Free article.
Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc subgroup analysis of the ORIGAMI study.
Azuma T, Misaki K, Kusaoi M, Suzuki Y, Higa S, Kumon Y, Yoshitama T, Naniwa T, Yamada S, Okano T, Takeuchi K, Ikeda K, Higami K, Inoo M, Sawada T, Kang C, Hayashi M, Nagaya Y, Hagiwara T, Shono E, Himeno S, Tanaka E, Inoue E, Yoshizawa Y, Kadode M, Yamanaka H, Harigai M. Azuma T, et al. Among authors: shono e. Mod Rheumatol. 2023 Mar 2;33(2):271-278. doi: 10.1093/mr/roac032. Mod Rheumatol. 2023. PMID: 35389481
Suppression of joint destruction with subcutaneous tocilizumab for Japanese patients with rheumatoid arthritis in clinical practice.
Nakashima Y, Kondo M, Shono E, Ishinishi T, Tsukamoto H, Kuroda K, Maeyama A, Harada H, Maekawa M, Shimauchi T, Nagamine R, Jojima H, Yoshizawa S, Tsuru T, Otsuka T, Miyahara H, Suematsu E, Wada K, Yoshizawa S, Inoue Y, Fukuda T, Ikemura S, Haraguchi A. Nakashima Y, et al. Among authors: shono e. Mod Rheumatol. 2020 Sep;30(5):807-815. doi: 10.1080/14397595.2019.1676369. Epub 2019 Oct 17. Mod Rheumatol. 2020. PMID: 31580188
Correction to: Effectiveness and safety of sarilumab in patients with rheumatoid arthritis: A multicenter, retrospective, inverse probability of treatment-weighted analysis based on the FRAB-registry.
Harada H, Kondo M, Maeyama A, Fukuda T, Ikemura S, Shono E, Tsuru T, Inoue Y, Yoshizawa S, Niiro H, Nakashima Y. Harada H, et al. Among authors: shono e. Clin Rheumatol. 2024 May;43(5):1787-1791. doi: 10.1007/s10067-024-06907-6. Clin Rheumatol. 2024. PMID: 38489137 No abstract available.
Hereditary angioedema in Japan: genetic analysis of 13 unrelated cases.
Yamamoto T, Horiuchi T, Miyahara H, Yoshizawa S, Maehara J, Shono E, Takamura K, Machida H, Tsujioka K, Kaneko T, Uemura N, Suzawa K, Inagaki N, Umegaki N, Kasamatsu Y, Hara A, Arinobu Y, Inoue Y, Niiro H, Kashiwagai Y, Harashima S, Tahira T, Tsukamoto H, Akashi K. Yamamoto T, et al. Among authors: shono e. Am J Med Sci. 2012 Mar;343(3):210-4. doi: 10.1097/MAJ.0b013e31822bdb65. Am J Med Sci. 2012. PMID: 21934598
Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.
Ogata A, Atsumi T, Fukuda T, Hirabayashi Y, Inaba M, Ishiguro N, Kai M, Kawabata D, Kida D, Kohsaka H, Matsumura R, Minota S, Mukai M, Sumida T, Takasugi K, Tamaki S, Takeuchi T, Ueda A, Yamamoto K, Yamanaka H, Yoshifuji H, Nomura A; Musashi Study Investigators. Ogata A, et al. Arthritis Care Res (Hoboken). 2015 Oct;67(10):1354-62. doi: 10.1002/acr.22598. Arthritis Care Res (Hoboken). 2015. PMID: 25832859 Free PMC article. Clinical Trial.
Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).
Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Shono E, Ishida Y, Tarumi E, Imai M. Ohta S, et al. Among authors: shono e. J Clin Pharmacol. 2014 Jan;54(1):109-19. doi: 10.1002/jcph.185. Epub 2013 Oct 12. J Clin Pharmacol. 2014. PMID: 24115082 Free PMC article. Clinical Trial.
22 results